NCT02038816 - Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

September 29, 2016

Study Completion Date

September 29, 2016

Conditions

Myelodysplastic Syndromes

Interventions

DRUG

Deferasirox + Azacitidine

"Deferasirox:~20 mg/kg/d for \< 14ml/kg/mo pRBCs (\~ \<4U/mo), 30mg/kg/d for ≥14ml/kg/mo pRBCs(≥4U/mo), 10mg/kg/d for transfusion-independent patients"

DRUG

Azacitidine

Azacitidine 75mg/m2 sc daily X 7 days (5-2-2 schedule permitted) on a 28 day cycle for 6 cycles

Trial Locations (1)

M4N 3M5

Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto